Literature DB >> 15273832

Plasmapheresis in the treatment of myasthenia gravis: retrospective study of 26 patients.

Rosana Carandina-Maffeis1, Anamarli Nucci, José F C Marques, Eduardo G Roveri, Beatriz H M Pfeilsticker, Solange G Garibaldi, Leonardo de Deus-Silva.   

Abstract

We analyzed the experience of Unicamp Clinical Hospital with plasma exchange (PE) therapy in myasthenia gravis (MG). About 17.8 % of a totality of MG patients had PE performed: 26 cases, 19 women and seven men. The mean age-onset of MG was 28 years, extremes 11 and 69. Minimum deficit observed in the group was graded IIb (O & G) or IIIa (MGFA scale). One patient had prethymectomy PE. In seven the procedures were performed due to myasthenic crisis and in 18 patients due to severe myasthenic symptoms or exacerbation of previous motor deficit. Two patients were also submitted to chronic PE considering refractoriness to other treatments. Twenty-six patients had 44 cycles of PE and 171 sessions. The mean number of sessions was 3.9 (SD +/- 1.4) each cycle; median 5, extremes 2 and 6. The mean time by session was 106,5 minutes (SD +/- 35.2); median 100.5 (extremes of 55 and 215). The mean volume of plasma exchanged in each session was 2396 ml (SD +/- 561); median 2225 (extremes 1512 and 4500). Side effects occurred: reversible hypotension (seven cases), mild tremor or paresthesias (seven cases). Infection and mortality rates due to PE were zero. All patients had immediate benefit of each PE cycle and usually they also received prednisone or other immunosuppressors. Good acceptance of the procedure was observed in 80.7% of patients.

Entities:  

Mesh:

Year:  2004        PMID: 15273832     DOI: 10.1590/s0004-282x2004000300003

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  4 in total

1.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

2.  Therapeutic plasma exchange in the treatment of myasthenia gravis.

Authors:  Rajesh Kumar; S Paul Birinder; Sonia Gupta; Gagandeep Singh; Amarjit Kaur
Journal:  Indian J Crit Care Med       Date:  2015-01

3.  Our Clinical Experience in the Treatment of Myasthenia Gravis Acute Exacerbations with a Novel Nanomembrane-Based Therapeutic Plasma Exchange Technology.

Authors:  Dimitar Tonev; Radostina Georgieva; Evgeniy Vavrek
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

4.  No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.

Authors:  Lulu Wang; Shumin Wang; Haonan Yang; Jiaojiao Han; Xue Zhao; Sensen Han; Yingna Zhang; Jie Lv; Jing Zhang; Mingqiang Li; Ying Ji; Shuxian Zhou; Xiaoxiao He; Hua Fang; Junhong Yang; Yunke Zhang; Qingyong Zhang; Peiyang Gao; Feng Gao
Journal:  Brain Behav       Date:  2021-06-02       Impact factor: 2.708

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.